Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.10.2 (
focal adhesion kinase
)
44,029
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The biological role of
vacuolar protein sorting 33B
(
VPS33B
) has not been examined in colorectal cancer (CRC). We report that
VPS33B
was downregulated in dextran sulfate sodium/azoxymethane (DSS/AOM) -induced CRC mice models and nicotine-treated CRC cells via the PI3K/AKT/c-Jun pathway. Reduced
VPS33B
is an unfavorable factor promoting poor prognosis in human CRC patients.
VPS33B
overexpression suppressed CRC proliferation, intrahepatic metastasis and chemoresistance of cisplatin (DDP) in vivo and in vitro through modulating the epidermal growth factor receptor (EGFR)/RAS/ERK/c-Myc/p53/miR-133a-3p feedback loop and the downstream cell cycle or
EMT
-related factors. Furthermore, NESG1 as a newly identified tumor suppressor interacted with
VPS33B
via colocalization in the cytoplasm, and it was stimulated by
VPS33B
through the downregulation of RAS/ERK/c-Jun-mediated transcription. NESG1 also activated
VPS33B
expression via the RAS/ERK/c-Jun pathway. Suppression of NESG1 increased cell growth, migration and invasion via the reversion of the
VPS33B
-modulating signal in
VPS33B
-overexpressed cells. Taken together,
VPS33B
as a tumor suppressor is easily dysregulated by chemical carcinogens and it interacts with NESG1 to modulate the EGFR/RAS/ERK/c-Myc/p53/miR-133a-3p feedback loop and thus suppress the malignant phenotype of CRC.
...
PMID:VPS33B negatively modulated by nicotine functions as a tumor suppressor in colorectal cancer. 3112 23